EUVIMEDEUVIMED entdecken
Open Access

Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor

Zeta Chow, Jeremy Johnson, Aman Chauhan, Jong Cheol Jeong, Jennifer T Castle, Tadahide Izumi, Heidi Weiss, Courtney M Townsend, Jörg Schrader, Lowell Anthony, Eddy S Yang, B Mark Evers und 1 weitere

Cancer Letters · 2024-08 · 596 · 216993

DOI: 10.1016/j.canlet.2024.216993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Zeta Chow und 12 weiteren Autor:innen. Beteiligte Einrichtung: Markey Cancer Center, Lexington, KY, USA; Department of Radiation Medicine, University of Kentucky, Lexington, KY, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Ribonucleoside Diphosphate Reductase, Radiation-Sensitizing Agents, Apoptosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ribonucleotide Reductase (RNR) is a rate-limiting enzyme in the production of deoxyribonucleoside triphosphates (dNTPs), which are essential substrates for DNA repair after radiation damage. We explored the radiosensitization property of RNR and investigated a selective RRM2 inhibitor, 3-AP, as a radiosensitizer in the treatment of metastatic pNETs. We investigated the role of RNR subunit, RRM2, in pancreatic neuroendocrine (pNET) cells and responses to radiation in vitro. We also evaluated the selective RRM2 subunit inhibitor, 3-AP, as a radiosensitizer to treat pNET metastases in vivo. Knockdown of RNR subunits demonstrated that RRM1 and RRM2 subunits, but not p53R3, play significant roles in cell proliferation. RRM2 inhibition activated DDR pathways through phosphorylation of ATM and DNA-PK protein kinases but not ATR. RRM2 inhibition also induced Chk1 and Chk2 phosphorylation, resulting in G1/S phase cell cycle arrest. RRM2 inhibition sensitized pNET cells to radiotherapy and induced apoptosis in vitro. In vivo, we utilized pNET subcutaneous and lung metastasis models to examine the rationale for RNR-targeted therapy and 3-AP as a radiosensitizer in treating pNETs. Combination treatment significantly increased apoptosis of BON (human pNET) xenografts and significantly reduced the burden of lung metastases. Together, our results demonstrate that selective RRM2 inhibition induced radiosensitivity of metastatic pNETs both in vitro and in vivo. Therefore, treatment with the selective RRM2 inhibitor, 3-AP, is a promising radiosensitizer in the therapeutic armamentarium for metastatic pNETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsRibonucleoside Diphosphate ReductaseRadiation-Sensitizing AgentsApoptosisCell ProliferationXenograft Model Antitumor AssaysRadiation ToleranceMice, NudeHumansAnimalsCell Line, TumorPhosphorylationNeuroendocrine TumorsLung NeoplasmsAtaxia Telangiectasia Mutated ProteinsTumor Suppressor ProteinsSignal TransductionCheckpoint Kinase 1MiceCheckpoint Kinase 2FemaleRNA InterferenceDNA-Activated Protein Kinase

Stichwörter der Autor:innen

MetastasesPancreatic neuroendocrine tumorRadiosensitizationRadiotherapyRibonucleotide reductase inhibitor

Substanzen

Ribonucleoside Diphosphate Reductaseribonucleotide reductase M2Radiation-Sensitizing AgentsRRM1 protein, humanAtaxia Telangiectasia Mutated ProteinsTumor Suppressor ProteinsCheckpoint Kinase 1ATM protein, humanCHEK1 protein, humanPRKDC protein, human

Autor:innen und Institutionen

  • Markey Cancer Center, Lexington, KY, USA; Department of Radiation Medicine, University of Kentucky, Lexington, KY, USA.
  • Markey Cancer Center, Lexington, KY, USA.
  • Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
  • Markey Cancer Center, Lexington, KY, USA; Department of Internal Medicine, Division of Biomedical Informatics, University of Kentucky, Lexington, KY, USA.
  • Markey Cancer Center, Lexington, KY, USA; Department of Surgery, University of Kentucky, Lexington, KY, USA.
  • Markey Cancer Center, Lexington, KY, USA; Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Chow, Z., Johnson, J., Chauhan, A., Jeong, J. C., Castle, J. T., Izumi, T., Weiss, H., Townsend, C. M., Schrader, J., Anthony, L., Yang, E. S., Evers, B. M., & Rychahou, P. (2024). Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor. Cancer Letters, 596, 216993. https://doi.org/10.1016/j.canlet.2024.216993

Vancouver

Chow Z, Johnson J, Chauhan A, Jeong JC, Castle JT, Izumi T, et al. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor. Cancer Letters. 2024;596:216993. doi:10.1016/j.canlet.2024.216993

BibTeX
@article{Chow2024,
  author = {Chow, Zeta and Johnson, Jeremy and Chauhan, Aman and Jeong, Jong Cheol and Castle, Jennifer T and Izumi, Tadahide and Weiss, Heidi and Townsend, Courtney M and Schrader, Jörg and Anthony, Lowell and Yang, Eddy S and Evers, B Mark and Rychahou, Piotr},
  title = {Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor},
  journal = {Cancer Letters},
  year = {2024},
  volume = {596},
  pages = {216993},
  doi = {10.1016/j.canlet.2024.216993}
}
Kostenlos starten →